Evidence map›Paper›PMID 28169278›Full record

ArticleScientific reports2017

Improving the therapeutic efficacy of mesenchymal stromal cells to restore perfusion in critical limb ischemia through pulsed focused ultrasound.

Pamela A Tebebi, Saejeong J Kim, Rashida A Williams, Blerta Milo, Victor Frenkel, Scott R Burks, Joseph A Frank

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Cytosolic CaTheranostics · 2021
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Pamela A TebebiFrank Lab, Radiology and Imaging Sciences Dept., Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Saejeong J KimFrank Lab, Radiology and Imaging Sciences Dept., Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Rashida A WilliamsFrank Lab, Radiology and Imaging Sciences Dept., Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Blerta MiloFrank Lab, Radiology and Imaging Sciences Dept., Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Victor FrenkelDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Scott R BurksFrank Lab, Radiology and Imaging Sciences Dept., Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Joseph A FrankFrank Lab, Radiology and Imaging Sciences Dept., Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health Clinical Center · USCatholic University of America · USNational Institutes of Health · USUniversity of Maryland, Baltimore · US

Funding

Preclinical high intensity focused ultrasound: mechanisms and applicationsZIACL040014 · CLC · CLINICAL CENTER · PI FRANK, JOSEPH · 2009 to 2025
$0k
6 · The paper itself

Abstract

Mesenchymal stem cells (MSC) are promising therapeutics for critical limb ischemia (CLI). Mechanotransduction from pulsed focused ultrasound (pFUS) upregulates local chemoattractants to enhance homing of intravenously (IV)-infused MSC and improve outcomes. This study investigated whether pFUS exposures to skeletal muscle would improve local homing of iv-infused MSCs and their therapeutic efficacy compared to iv-infused MSCs alone. CLI was induced by external iliac arterial cauterization in 10-12-month-old mice. pFUS/MSC treatments were delayed 14 days, when surgical inflammation subsided. Mice were treated with iv-saline, pFUS alone, IV-MSC, or pFUS and IV-MSC. Proteomic analyses revealed pFUS upregulated local chemoattractants and increased MSC tropism to CLI muscle. By 7 weeks post-treatment, pFUS + MSC significantly increased perfusion and CD31 expression, while reducing fibrosis compared to saline. pFUS or MSC alone reduced fibrosis, but did not increase perfusion or CD31. Furthermore, MSCs homing to pFUS-treated CLI muscle expressed more vascular endothelial growth factor (VEGF) and interleukin-10 (IL-10) than MSCs homing to non-pFUS-treated muscle. pFUS + MSC improved perfusion and vascular density in this clinically-relevant CLI model. The molecular effects of pFUS increased both MSC homing and MSC production of VEGF and IL-10, suggesting microenvironmental changes from pFUS also increased potency of MSCs in situ to further enhance their efficacy.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationReperfusionUltrasonic WavesAnimalsBiomarkersDisease Models, AnimalExtremitiesFemaleFibrosisInterleukin-10IschemiaMiceMuscle, SkeletalProteomeProteomicsBiomarkersInterleukin-10ProteomeVascular Endothelial Growth Factor A

Identifiers

PMID28169278
PMCPMC5294408
OpenAlexW2586159892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.